文献速递神经肿瘤

端粒替代延长介导的永生化使H3G34R突变弥漫性半球胶质瘤对PARP抑制剂联合方案超敏

Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens.
PubMed 文献 · Neuro Oncol · 2025-01-01

本研究探讨H3G34R突变合并ATRX缺失的弥漫性半球胶质瘤中端粒替代延长(ALT)现象及其对PARP抑制剂联合治疗的敏感性。患者来源模型和iPSCs显示ALT表型伴基础DNA损伤应激增加,对talazoparib或niraparib联合拓扑异构酶-I抑制剂(拓扑替康、伊立替康)呈协同敏感;一例患者接受niraparib联合拓扑替康后肿瘤显著缩小。结论支持进一步开发PARP抑制剂联合DNA损伤应激诱导方案。

要点

  • H3G34R突变合并ATRX缺失的弥漫性半球胶质瘤以端粒替代延长(ALT)为关键特征。
  • ALT表型伴基础DNA损伤应激增加,对PARP抑制剂联合拓扑异构酶-I抑制剂协同敏感。
  • 首例患者接受niraparib联合拓扑替康治疗后肿瘤显著缩小。

核心结论

  • 临床前和临床数据强烈支持进一步开发PARP抑制剂联合DNA损伤应激诱导方案用于DHG-H3G34R_ATRX。

研究设计与样本

  • 研究使用患者来源的原发性儿童高级别胶质瘤模型、人诱导多能干细胞(iPSCs)、鸡胚绒毛尿囊膜(CAM)和原位体内实验,并治疗了一例DHG-H3G34R_ATRX患者。

主要发现

  • ALT是DHG-H3G34R_ATRX的关键特征,H3G34R与ATRX缺失在ALT激活中呈显性协作效应,在iPSCs中亦显现。
  • 患者来源DHG-H3G34R_ATRX模型和H3G34R+/ATRX- iPSCs中,ALT表型与基础DNA损伤应激增加相关,介导对PARP抑制剂(talazoparib、niraparib)联合拓扑异构酶-I抑制剂(拓扑替康、伊立替康)的协同敏感。
  • 首例DHG-H3G34R_ATRX患者接受脑渗透性PARP抑制剂niraparib联合拓扑替康治疗,肿瘤显著缩小。

临床怎么用

  • 作者认为临床前和临床数据强烈支持进一步开发PARP抑制剂联合DNA损伤应激诱导方案用于DHG-H3G34R_ATRX。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse hemispheric glioma, H3 G34R/V-mutant (DHG-H3G34) is characterized by poor prognosis and lack of effective treatment options. DHG-H3G34R further harbor deactivation of alpha-thalassemia/mental retardation syndrome X-linked protein (ATRX; DHG-H3G34R_ATRX) suggesting a unique interaction of these 2 oncogenic alterations. In this study, we dissect their cell biological interplay, investigate the impact on telomere stabilization, and consequently validate a targeted therapy approach. METHODS: We characterized patient-derived primary pediatric high-grade glioma (pHGG) models for telomere-maintenance mechanisms, DNA damage stress (including protein expression, pH2AX/Rad51 foci, cell-cycle arrest) and their sensitivity towards poly-ADP ribose polymerase inhibitor (PARPi) combinations. Human induced pluripotent stem cells (iPSCs) were used for modeling the disease. The anticancer activity of PARPi combinations in vivo was studied in Chorioallantoic Membrane (CAM) and orthotopic in vivo experiments. Finally, we treated a DHG-H3G34R_ATRX patient with PARPi combination therapy. RESULTS: We elaborate that alternative lengthening of telomeres (ALT) is a key characteristic of DHG-H3G34R_ATRX. A dominant cooperative effect between H3G34R and ATRX loss in ALT activation also became apparent in iPSCs, which endogenously exert telomerase activity. In both, patient-derived DHG-H3G34R_ATRX models and H3G34R+/ATRX- iPSCs, the ALT-phenotype was associated with increased basal DNA damage stress, mediating synergistic susceptibility towards PARPi (talazoparib, niraparib) combinations with topoisomerase-I inhibitors (topotecan, irinotecan). In a first-of-its-kind case, treatment of a DHG-H3G34R_ATRX patient with the brain-penetrant PARP inhibitor niraparib and topotecan resulted in significant tumor reduction. CONCLUSIONS: Our preclinical and clinical data strongly support the further development of PARPi together with DNA damage stress-inducing treatment regimens for DHG-H3G34R_ATRX.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Laemmerer A, Lehmann C, Mayr L, et al. Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens. Neuro Oncol. 2025. PMID: 39556024. doi:10.1093/neuonc/noae228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。